Kolltan Pharmaceuticals to Present KTN0158 Preclinical Data at the European Cancer Congress 2015

NEW HAVEN, Conn.--()--Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases, today announced that the Company will present preclinical data from a study evaluating KTN0158 in dogs with mast cell tumors conducted by Dr. Cheryl London at The Ohio State University during the European Cancer Congress 2015. The conference is hosted by the European Society for Medical Oncology (ESMO) and will be held in Vienna, Austria, September 25-29, 2015. KTN0158 is a proprietary humanized anti-KIT monoclonal antibody for which Kolltan plans to file an IND with the FDA in 2015.

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Antitumor Activity in Dogs with Mast Cell Tumors (Abstract No. 202)

Authors: Cheryl London, Sarah Rippy, William Kisseberth, Gerald Post, Neal Janson, Linda Crew, Theresa LaVallee, Richard Gedrich. The Ohio State University, Columbus, OH, USA; The Veterinary Cancer Center, Norwalk CT, USA; Kolltan Pharmaceuticals, Inc., New Haven, CT, USA

Speaker: Richard Gedrich, Ph.D., Director, Translational Medicine, Kolltan Pharmaceuticals

Session Title: Translational Research (Hall C)

Session Date/ Time: Monday, September 28, 2015, 4:45 to 6:45pm CET

About KTN0158:

KTN0158 is a proprietary humanized monoclonal antibody designed using structure based approaches to block the activation of KIT, a receptor tyrosine kinase that is expressed in many cancers and plays an important role in regulating mast cells. While there are several successful currently marketed small molecule products targeting KIT, there are no therapeutic antibodies targeting KIT on the market. KIT has been demonstrated to play a role in the progression of several tumor types and may contribute to immune evasion of tumors. Further, KIT signaling regulates the activation of mast cells, immune cells involved in the onset and progression of inflammatory diseases such as neurofibromatosis type 1, allergy, and asthma.

About Kolltan Pharmaceuticals

Kolltan, a privately held clinical-stage company, is focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases with significant unmet need. Kolltan’s founders and members of its management team have deep expertise and a proven track record in drug discovery, development, and commercialization of innovative therapeutics, including drugs targeting kinases. Kolltan is working in close collaboration with the laboratory of Kolltan Co-Founder, Dr. Joseph Schlessinger, as well as the Yale University medical and scientific community. The Company has a broad and novel portfolio of therapeutic biologics targeting multiple receptor tyrosine kinases that are advancing in clinical and preclinical development and are progressing toward potential achievement of multiple near-term milestones.

Contacts

Media Inquiries:
Burns McClellan
Justin Jackson, 212-213-0006
jjackson@burnsmc.com
or
Investor Inquiries:
Kolltan Pharmaceuticals, Inc.
Jay Campbell, 203-907- 0938